Overview
Beckley Psytech is a UK-based clinical-stage company developing short-duration psychedelic therapies, with a lead program using intranasal psilocybin (BPL-003) for treatment-resistant depression intended to reduce session time versus oral formulations. They are part of the Beckley Foundation's broader mission to advance psychedelic science.
More in Psychedelics
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🍄 Psychedelics
Location
Oxford, UK
Funding
Series B · $80M
Website
www.beckleypsytech.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →